InvestigationalLate-stage / investigational

Retatrutide

Also known as:LY3437943triple Gtriple agonist

Class: Late-stage / investigational
Route: SC injection
Frequency: Once weekly in trials
GLP-1 relevance: Yes

How it works

Triple GIP/GLP-1/glucagon receptor agonist

Approved & studied uses

Obesity / metabolic disease pipeline

Regulatory status

Investigational — not FDA-approved as of 4 August 2026

Safety notes

No approved human dosing. App should require custom/manual schedule and disclaimer.

Sources

Retatrutide NEJM/PubMed

Educational reference only. This page does not provide diagnosis, dosing, titration or treatment recommendations. Peptimize does not recommend or adjust any medication schedule - that is between you and your prescriber.